iwCAR-T 2022

28 Apr–01 May 2022 | Tampa, FL / Online

The 4th International Workshop on CAR-T (iwCAR-T) took place on 28 April – 1 May 2022 in Tampa, FL, with VJHemOnc & VJOncology as official media partners. The workshop is a high-level discussion forum for research leaders in the field of CAR-T to share their perspectives on how to place this evolving understanding in a clinical context and thereby optimize clinical care. This year, a full day was dedicated to CAR-T therapy for solid cancers.

Emerging CARs and Future Challenges GU Cancers Lung Cancers Breast and ovarian Cancers GI Cancers Head/neck and CNS Cancers Melanoma, Sarcomas

Session I: Emerging CARs and future challenges in solid tumors

Julian Molina

Clinical perspective IO/TILs to BiTEs to TCR to CARs

Julian Molina Mayo Clinic, Rochester, MN

Kim Reiss Binder

anti-HER2 CAR macrophages in solid tumors

Kim Reiss Binder University of Pennsylvania, Philadelphia, PA

Daniel Wang

Human iPSC-derived CAR-Ts with T-cell anti-tumor activity

Daniel Wang City of Hope, Duarte, CA

Session 2: GU cancers

Vivek Narayan

PSMA-redirected Armored CAR-Ts for mCRPC

Vivek Narayan University of Pennsylvania, Philadelphia, PA

Joseph Fraietta

Armored CAR-T therapy in mPC

Joseph Fraietta University of Pennsylvania, Philadelphia, PA

Susan Slovin

P-PSMA-101 CAR-Ts for mCRPC

Susan Slovin Memorial Sloan Kettering Cancer Center, New York, NY

David Hong

MAGE-A4 TCR for solid tumors

David Hong The University of Texas MD Anderson Cancer Center

Session 3: CAR-T clinical advances in solid tumors – lung

Sandip Patel

Landscape overview

Sandip Patel UC San Diego Health, San Diego, CA

Sylvia Lee

TILs treatment for lung cancer

Sylvia Lee Fred Hutchinson Cancer Research Center, Seattle, WA

Shivani Srivastava

Overcoming barriers to CAR-T therapy in solid tumors

Shivani Srivastava Fred Hutchinson Cancer Research Center, Seattle, WA

Melissa Johnson

‘Off-the-shelf’ PRBCs and iNKT cells

Melissa Johnson Sarah Cannon Research Institute, Nashville, TN

Session 4: Breast and ovarian cancers

Jose Conejo-Garcia

CER T-cell technology for ovarian cancer

Jose Conejo-Garcia H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Winfried Alsdorf

BNT211: CLDN6 CAR-Ts & CARVac-based CAR-T in vivo expansion

Winfried Alsdorf University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Session 5: GI cancers

Joel Randolph Hecht

I-O to cell therapy; IO/T-VEC, BiTEs/TCRs

Joel Randolph Hecht UCLA Health, Los Angeles

Diane Simeone

Precision Promise: an adaptive phase 2/3 platform for drug development

Diane Simeone NYU Langone Health, New York City, NY

Mark O'Hara

HuCART-meso cells in patients with pancreatic cancer

Mark O'Hara University of Pennsylvania, Philadelphia, PA

William Go

The future of logic-gated cell therapy

William Go A2 Biotherapeutics, Agoura Hills, CA

Session 6: Head/neck and CNS cancers

Kedar Kirtane

Cellular immunotherapy in head and neck cancers

Kedar Kirtane H. Lee Moffitt Cancer Center & Research Institute

Session 7: Melanoma, sarcomas

Sylvia Lee

TILs for metastatic melanoma

Sylvia Lee Fred Hutchinson Cancer Research Center, Seattle, WA

The 4th International Workshop on CAR-T has been supported by: